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guidelines, and TG-101. Cosmesis was assessed using the 
Harvard Breast Cosmesis Scale.  
 
Results: Twenty patients were treated successfully. At a 
median follow-up of 18 months (1-78), all patients remain 
locally controlled (100%) and no significant adverse events 
have occurred. All patients continue to experience good-
excellent cosmetic outcomes. At least 3 fiducials were 
tracked in 85% of cases. Fiducial tracking was not successful 
in one patient. The mean number of beams delivered was 145 
(77-196). The mean treated PTV30Gy was 74 cm3 (15-142 
cm3) with a mean prescription isodose line of 82% (75-86%). 
99% of the PTV30Gy received the prescription dose (95-100%) 
with a mean maximum dose of 36 Gy (34.5-40Gy). The mean 
ipsilateral breast V30Gy and V15Gy were 12% (3-26%) and 30% 
respectively (8-58%) sparing significant amounts of normal 
breast tissue. Patient tolerance was excellent and acute 
toxicity was rarely observed. 2 patients experienced grade 1 
localized dermatitis at the initial 4 week follow-up visit. 
 
Conclusions: CyberKnife stereotactic accelerated partial 
breast irradiation is a suitable radiotherapy technique for the 
delivery of partial breast irradiation. The CK platform 
produces highly conformal treatments with excellent normal 
tissue sparing and offers improvements over existing PBI 
techniques. Our experience indicates that CK-SAPBI delivered 
in five fractions is well tolerated with excellent short term 
local control and breast cosmesis. Longer follow-up is needed 
for assessment of late toxicity and oncologic outcomes.  
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Purpose or Objective: The voluntary deep-inspiration 
breath-hold radiotherapy technique (DIBHRT) in the 
treatment of left breast cancer has the ability to reduce 
doses to heart left anterior descending coronary artery (LAD) 
and lung. Before introduction of DIBHRT into routine clinical 
practice, we conducted a prospective study to assess the 
extent of dosimetric benefit of this technique in order to 
select a group of patients for whom this technique should be 
routinely applied 
 
Material and Methods: Thirty one consecutive patients 
qualified for whole breast irradiation (WBI) with tangential 
fields following breast conserving surgery for left-sided early 
breast cancer were included. All patients underwent breath-
hold training, free-breathing (FB) and DIBH planning-CT. 
Separate radiotherapy treatment plans for WBI in total dose 
of 39.9Gy in 15 fraction were prepared based on both 
planning-CT. Doses like mean heart, heart V20Gy, maximum 
LAD, left lung V20Gy were calculated for each plan and the 
difference of respective values (delta) for FB and DIBH were 
calculated. If relative improvement of at least 20%for any 
evaluated dosimetric parameter were found for DIBH plan 
without significant worsening of other measures, this plan 
was selected for treatment. Daily tree-dimensional surface 
imaging (VisionRT) and weekly electronic portal imaging were 
performed. The data distribution were assessed using chi² 
test, correlations were analyzed using the Pearson test. 
Furthermore, receiver operating characteristic (ROC) analysis 
was performed. 
 
Results: In 30 of 31 patents a reduction at least 20% in one or 
more evaluated parameters (i.e.mean heart, heart V20Gy, 
maximum LAD and left lung V20Gy in 29, 29, 26, and 7 
patents respectively)was achieved. The relative worsening of 
left lung V20Gy was found for in 10 and cases and of 
maximum LAD in 2 cases. Eventually 25 patients were 
qualified to DIBHRT. Mean delta(Gy) were:mean heart 1.51 
(range:0.06-6.45),heart V20Gy:3.0 (range:0.0-6.59),maximum 
LAD:18.5(range:-3.29-36.68), left lung V20Gy:1.7(range:-
2.71-8.7). Correlations between delta values of mean heart, 
maximum LAD, heart V20Gy with length of cardiac contact 
distance (CCD) (p< 0.05, AUC>0,6) and maximum LAD, heart 
V20Gy with Body Mass Index (BMI)(p<0.05;AUC>0.6) were 
found. ROC analysis showed that a 2.5 cm of CCD is a 
threshold for reduction at least 20% in one or more 
parameters. For BMI no specific threshold for predefined 
improvement of any dosimetric parameter was identified, 
which means that despite correlation of dosimetric cardiac 
benefit with higher BMI, some patients with low BMI may also 
have cardiac doses reduced with DIBHRT. 
 
Conclusion: In our center we have prospectively confirmed 
an ability of DIBHRT for heart and LAD but not for lung-
sparing. We are going to use this technique routinely for left-
sided breast cancer patients with CCD above 2.5 cm 
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Purpose or Objective: Post-mastectomy radiation therapy 
(PMRT) is standard care for breast cancer patients with high 
risk for locoregional recurrence after mastectomy. The 
indication for PMRT in patients with 1 to 3 positive nodes has 
been in discussion. We reported that patients concomitantly 
with 1 to 3 positive nodes and extensive lymphatic invasion, 
who had not been treated with PMRT from 1990 to 2000, had 
13.1% (12/92) of locoregional recurrence rate. Since then we 
have performed PMRT for patients with 1 to 3 positive nodes 
and extensive lymphatic invasion. 
To investigate the effectiveness of PMRT for patients with 1 
to 3 positive nodes and extensive lymphatic invasion. 
 
Material and Methods: Between 2005 and 2013, 639 patients 
were treated with PMRT and 277 patients of those have not 
been without neoadjuvant chemotherapy until the lymph 
node dissection. Among these patients, 81 were diagnosed 
with 1 to 3 positive nodes pathologically, 65 were with 1 to 3 
positive nodes and extensive lymphatic invasion. The 3-D 
conformal RT, using the partial wide tangent technique to 
the chest wall, internal mammary lymph nodes and supra-
clavicular nodes, was applied for all patients, delivering 50 
Gy in 25 fractionation over 5 weeks. In the patients with 
positive surgical margin, 10 Gy of electron boost to the tumor 
bed was added. We retrospectively reviewed and compared 
locoregional recurrence rates of 65 patients with 1 to 3 
positive nodes and extensive lymphatic invasion treated with 
PMRT and that of 92 patients without PMRT. 
 
Results: Baseline patient characteristics; the median age of 
these patients was 47 years old (range; 34-76). Survivals; the 
median duration of overall survival was 114 months (30 to 
121 months), the five-year survival rate is 97%, and the 
median progression-free survival time after PMRT was 93 
months (7.0 to 110 months). Of the 65 patients in the current 
analysis, 58 patients (89%) were alive and free of cancer. 
Initial failure patterns; the locoregional recurrence was 
observed in 3 patients (4.6%), classifying into 1 chest wall, 1 
regional lymph node, and 1 both. All patients with 
locoregional recurrence were developed the distant 
metastases then after. As toxicity; radiation induced 
pneumonitis graded 1 was observed in 9 patients, nor been 
graded 2 or more observed. Acute radiation induced 
dermatitis was observed almost all patients at least grade 1, 
grade3 was observed in 9 patients. One patient denied 
continuing PMRT at dose of 46Gy, 7 months later her chest 
wall recurrence was observed. 
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Conclusion: The 4.6% of local recurrence rate of PMRT cohort 
registered from 2005 to 2013 was lower than 13.1% (12/92) of 
non-PMRT cohort registered from 1990 to 2000. 
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Purpose or Objective: The aim of our study was to 
determine the impact of nodal status and other prognostic 
factors on clinical outcome of patients with breast cancer 
treated with surgery and adjuvant radiotherapy. 
 
Material and Methods: A total of 774 breast cancer patients 
treated between 2001 and 2013 were retrospectively 
analyzed. Qualitative and quantitative characteristics were 
summarized as frequencies and percentages, average and 
standard deviations. The rates of Overall Survival (OS), 
disease free survival (DFS), and loco-regional recurrence (LR) 
were calculated at 36 and 60 months with the Kaplan-Meier 
method. Multivariate analysis was also performed and a p 
value of 0.05 was considered statistically significant. 
 
Results: We identified 774 patients treated with adjuvant RT 
of which 595 patients (75.4%) without nodal involvement 
(pN0), 118 (14.9%) pN1-3 and 61 (7.75%) with more than 3 
positive lymph nodes (pN>3). In our sample, supra-clavicular 
region was irradiated in 62 patients (13 pN>3, 17 pN1-3, 32 
pN0). Median follow-up was 36 months (range 1-144 months). 
There were 14 cases of LR, of which 13 in pN0 and 1 in pN1-3 
patients. A total of 31 patients developed distant metastases 
(48.4% in pN0, 19.4% in pN1-3, 32.2% in pN>3 group). The 
mortality rate was of 2.8% (68.1% pN0, 18.2% pN1-3 and 
13.6% pN>3). There were no statistically significant 
differences in terms of OS, DFS and MFS among the three 
treatment groups. Multivariate analysis showed that clinical 
outcomes were significantly correlated with margin status (p-
value: 0.00), T-stage (p-value: 0.053), Her2-neu gene 
amplification (p-value: 0.00), Ki-67 (p-value: 0.00) and SCRT 
(p-value:0.00). Variables such as age, surgery, ER and PgR 
expression and grading, were not significant. 
 
Conclusion: In our study we observed higher rates of events 
in pN0 and pN1-3 patients, but none statistically significance 
was demonstrated between pN0, pN1-3 and pN>3 in terms of 
OS, DFS and MFS. Furthermore pN0 was in this experience the 
bigger group and this certainly influenced statistical analysis. 
In breast cancer, nodal status plays a key role both in the 
prognostic evaluation and in the therapeutic choice, and the 
clinical outcome of patients pN1-3 is comparable to pN>3 
patients; so in this group (pN1-3) it is also necessary the 
evaluation of other prognostic factors such as receptor 
status, Ki 67 and surgical margins. Nodal status alone seems 
incapable to really guide treatment choice, with particular 
regard to the SCRT appropriateness.  
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Purpose or Objective: The aim of this study was to evaluate 
treatment related complications and patient satisfaction in 
women with locally advanced breast cancer who received 
post-mastectomy radiation therapy after breast 
reconstruction. 
Material and Methods: Between 2009 and 2014, 65 patients, 
median age 48 years, with locally advanced breast cancer 
who underwent mastectomy with breast reconstruction in the 
same time, received post-mastectomy radiation therapy. Two 
patients received excision of local recurrence, 46 patients 
nipple sparing mastectomy, 10 skin sparing mastectomy and 7 
modified radical mastectomy. Post-mastectomy radiation 
therapy was delivered to the chest wall with a dose of 50 Gy 
in 25 fractions over 5 weeks (57 with 3Dconformal RT and 8 
with tomotherapy). 
 
Results: A patient interrupted radiation therapy to 20 Gy for 
severe acute toxicity with rejection of implants (delayed 
removal of the prosthesis). Acute dermal toxicity G2 for 
erythema, telangiectasia (1 patient) and edema was relieved 
in 26 patients, G1 toxicity in 36 patients, G0 in 2 patients and 
G3 in 1 patient. Two patients in systemic progression were 
not considered for local evaluation. At median follow-up of 
35 months: 43 patients presented late toxicity G1 due to 
hyperpigmentation, edema, periprothetic fibrosis. 7 patients 
referred sense of tension or pain and not satisfaction about 
the final aesthetic result. Two patients presented arm 
lymphedema. Two patients received replacing of the 
implants after 36 months due to contraction, encapsulation, 
dislocation, swelling. 
 
Conclusion: Radiotherapy can be safely delivered after 
breast reconstruction, with a low complication rate and good 
patient satisfaction. Further randomized studies are needed 
to better define the optimal management of breast 
reconstruction and post-mastectomy radiation therapy. 
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Purpose or Objective: The impact of adjuvant therapy on 
the surgical outcomes following breast reconstruction is 
poorly understood. The purpose of this work is to evaluate 
surgical outcomes following autologous and prosthetic 
reconstruction in the setting of post-mastectomy radiation 
therapy (PMRT) and adjuvant chemotherapy. We assessed the 
outcome and complications of irradiated patients in our 
department. 
 
Material and Methods: From May 2015 to July 2015 we 
analyzed acute, late toxicity and cosmetic results of 76 
patients with a median age of 50 ± 10 years undergoing 
mastectomy with immediate recostruction with prosthesis 
(79.7%), autologous technique (7.2%) or expander-implant 
(13%) following adjuvant radiotherapy. 24 patients underwent 
to Nac- Sparing Mastectomy, 10 of witch with periareolar 
pexy. 31 patients underwent to Skin reducing Mastectomy 
and 5 patients to Skin Sparing Mastectomy. The radiotherapy 
dose was 50 Gy to chest wall and supraclavicular limphnodes 
when indicated with 6 MV X-ray delivered with Linac (60pt), 
or with tomotherapy (16pt). 
 
Results: With a median follow-up of 25±24 months utilizing 
RTOG toxicity scale we observed a grade I acute toxicity in 
74.6% of patients, grade II in 6% of patients while in 19.4% of 
patients was not observed any sign of toxicity. Late toxicity 
was not observed in 68.7% of patients while in 28.4% of 
patients a grade I late toxicity was noted. No post-operative 
complications was observed in 62.3% of patients while in 
15.9% a capsular contracture was responsible in 20.3% of 
patients of explantation of prosthesis. None of patients 
developed post-operative skin ulcers. Cosmetic results was 
analyzed with Harvard Scale and was excellent in 4.5% of 
patients, good in 32.8%, fair in 16.4% and poor in 46.3%. The 
chi-test showed no correlation between early or late toxicity 
or cosmetics results with type of surgery (p>0.1). Univariate 
